CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

Advantages of Using Monoclonal Antibodies

Advantages of Using Monoclonal...

A Brief Overview Of Green Biotechnology Tools And Applications

A Brief Overview Of Green...

Key Advantages of Agtech in Farming

Key Advantages of Agtech in Farming

Nanotechnologys Impact on Environment: What to Know

Nanotechnologys Impact on...

How Automation in Pharmaceutical is Giving a New Direction to Drug Development

How Automation in Pharmaceutical is...

Ways Health Economics and Outcomes Research can Improve Decision Making Process

Ways Health Economics and Outcomes...

Top Agtech Industry Trends to Keep an Eye on

Top Agtech Industry Trends to Keep an...

Strategies to Mitigate Life Sciences Supply Chain Challenges

Strategies to Mitigate Life Sciences...

Protai to focus its study on the proteome to speed up drug discovery.

Life Sciences Review | Wednesday, January 19, 2022
Tweet

Protai, a startup, is working on proteomics, the study of proteins and their interactions after it raised an 8 million dollars seed round.


FREMONT, CA:With advances in processing power and algorithms, technology is becoming an increasingly important part of the complex drug discovery and testing process, and it is opening up new areas for analysis. Proteomics, the study of proteins and their interactions, is next up while Protai, a startup, is working on the 8 million dollars seed round it raised. Protai is placed below the cells and systems layer, where problems are visible as symptoms and above the genome and transcription level, where genetic factors can be identified. The largest proteomic database was put together by the company with some 50,000 samples from 6,000 papers, and harmonized the chaotic data where AI natural language was helpful so it can act as a single source of information.


 


Eran Seger, CEO and co-founder, explained the idea was not to analyze a small sample study but instead they intended to analyze all of the data out there on a specific disease but since proteins were collected and sequenced from a variety of conditions, instruments, protocols and controls it was like comparing apples to oranges. Anyway, by placing all the data together a higher level map of proteins and their interactions in the context of a particular given disease can be produced. Getting to know everything that can happen at a molecular level is always helpful. Seger further added that advances in biological explainability can give rise to better drug targets and drug candidates. Several high-value targets that are currently pursuing in the independent drug program can be pinpointed in the lung cancer proof of concept, along with other markers that can assist in expanding the utilization of known drugs into this indication. The company aims to gain the ability to span the drug discovery and testing process from tissue testing all the way to final clinical testing.


Weekly Brief

loading
Towards a New World Order
> <
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Proteomics 2022

    Top Vendors

    Current Issue

Read Also

Qualities to Consider when Choosing Life Sciences Business Consultants for Your Firm

How Biotech Startups can Mitigate Risks in Order to Grow Sustainably

Cellf BIO's BioShincter to Undergo Phase 1 Trail to Test Fecal Incontinence Treatment

Fulcrum Therapeutics Announces CEO Transition

An Overview of Wholesalers' Roles in Complex Supply Chains

Veeva Opening Up Integration Module for Future Opportunities and Applications

Veeva Systems To Accelerate the CRM of Life Science Businesses

The Role of Technology in Advancing Clinical Trials

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/protai-to-focus-its-study-on-the-proteome-to-speed-up-drug-discovery-nwid-694.html